MRC1 and neoplasm: It is also now therapeutically imperative to identify the status of expression of the MMR proteins/MSI as studies have shown that MMR deficient (d-MMR)/MSI-high (MSI-h) tumours demonstrate good response and prolonged survival on treatment with checkpoint inhibitors such as pembrolizumab and nivolumab [16,17].